570 related articles for article (PubMed ID: 24366360)
21. Genomic Landscape of Waldenström Macroglobulinemia.
Treon SP; Xu L; Liu X; Hunter ZR; Yang G; Castillo JJ
Hematol Oncol Clin North Am; 2018 Oct; 32(5):745-752. PubMed ID: 30190014
[TBL] [Abstract][Full Text] [Related]
22. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
[TBL] [Abstract][Full Text] [Related]
23. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
24. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
25.
Guerrera ML; Tsakmaklis N; Xu L; Yang G; Demos M; Kofides A; Chan GG; Manning RJ; Liu X; Chen JG; Munshi M; Patterson CJ; Castillo JJ; Dubeau T; Gustine J; Carrasco RD; Arcaini L; Varettoni M; Cazzola M; Treon SP; Hunter ZR
Haematologica; 2018 Sep; 103(9):e408-e411. PubMed ID: 29599202
[No Abstract] [Full Text] [Related]
26. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
Growkova K; Kufová Z; Sevcikova T; Filipová J; Kascak M; Jelínek T; Grosicki S; Barchnicka A; Roziaková Ľ; Mistrík M; Simicek M; Hájek R
Klin Onkol; 2017; 30(Supplementum2):81-91. PubMed ID: 28903575
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Moreno DF; López-Guerra M; Paz S; Oliver-Caldés A; Mena MP; Correa JG; Battram AM; Osuna M; Rivas-Delgado A; Rodríguez-Lobato LG; Cardús O; Tovar N; Cibeira MT; Jiménez-Segura R; Bladé J; Rosiñol L; Colomer D; Fernández de Larrea C
Br J Haematol; 2023 Jan; 200(2):187-196. PubMed ID: 36210485
[TBL] [Abstract][Full Text] [Related]
29. New treatment strategies for Waldenström macroglobulinemia.
Moreno DF; de Larrea CF; Castillo JJ
Clin Adv Hematol Oncol; 2022 Aug; 20(8):506-515. PubMed ID: 36125957
[TBL] [Abstract][Full Text] [Related]
30. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
31. Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.
Maclachlan KH; Bagratuni T; Kastritis E; Ziccheddu B; Lu S; Yellapantula V; Famulare C; Argyropoulos K; Derkach A; Papaemmanuil E; Dogan A; Lesokhin A; Usmani SZ; Landgren CO; Palomba LM; Maura F; Dimopoulos MA
Blood Adv; 2023 Mar; 7(6):971-981. PubMed ID: 36332058
[TBL] [Abstract][Full Text] [Related]
32. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions.
Schop RF; Kuehl WM; Van Wier SA; Ahmann GJ; Price-Troska T; Bailey RJ; Jalal SM; Qi Y; Kyle RA; Greipp PR; Fonseca R
Blood; 2002 Oct; 100(8):2996-3001. PubMed ID: 12351413
[TBL] [Abstract][Full Text] [Related]
33. MYD88 L265P mutation in Waldenstrom macroglobulinemia.
Poulain S; Roumier C; Decambron A; Renneville A; Herbaux C; Bertrand E; Tricot S; Daudignon A; Galiègue-Zouitina S; Soenen V; Theisen O; Grardel N; Nibourel O; Roche-Lestienne C; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Blood; 2013 May; 121(22):4504-11. PubMed ID: 23532735
[TBL] [Abstract][Full Text] [Related]
34. Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.
Magierowicz M; Tomowiak C; Leleu X; Poulain S
Hematol Oncol Clin North Am; 2018 Oct; 32(5):753-763. PubMed ID: 30190015
[TBL] [Abstract][Full Text] [Related]
35. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
[TBL] [Abstract][Full Text] [Related]
36. Cell-free DNA analysis for detection of MYD88
Demos MG; Hunter ZR; Xu L; Tsakmaklis N; Kofides A; Munshi M; Liu X; Guerrera ML; Leventoff CR; White TP; Flynn CA; Meid K; Patterson CJ; Yang G; Branagan AR; Sarosiek S; Castillo JJ; Treon SP; Gustine JN
Am J Hematol; 2021 Jul; 96(7):E250-E253. PubMed ID: 33819355
[No Abstract] [Full Text] [Related]
37. Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas.
Braggio E; Fonseca R
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):198-201. PubMed ID: 23477936
[TBL] [Abstract][Full Text] [Related]
38. Waldenstrom macroglobulinemia: genetics dictates clinical course.
Lenz G
Blood; 2014 May; 123(18):2750-1. PubMed ID: 24786453
[TBL] [Abstract][Full Text] [Related]
39. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Gustine JN; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ; Xu L
Br J Haematol; 2019 Jan; 184(2):242-245. PubMed ID: 30183082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
